Secretome Therapeutics has dosed the first patient in a Phase 1 trial evaluating STM-01, an allogeneic neonatal cardiac progenitor cell therapy for heart failure with preserved ejection fraction (HFpEF).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.